MDT

96.46

-0.47%↓

A

146.44

-1.03%↓

VEEV

228.35

-1.98%↓

HQY

84.03

-0.27%↓

NEOG

9.17

-1.5%↓

MDT

96.46

-0.47%↓

A

146.44

-1.03%↓

VEEV

228.35

-1.98%↓

HQY

84.03

-0.27%↓

NEOG

9.17

-1.5%↓

MDT

96.46

-0.47%↓

A

146.44

-1.03%↓

VEEV

228.35

-1.98%↓

HQY

84.03

-0.27%↓

NEOG

9.17

-1.5%↓

MDT

96.46

-0.47%↓

A

146.44

-1.03%↓

VEEV

228.35

-1.98%↓

HQY

84.03

-0.27%↓

NEOG

9.17

-1.5%↓

MDT

96.46

-0.47%↓

A

146.44

-1.03%↓

VEEV

228.35

-1.98%↓

HQY

84.03

-0.27%↓

NEOG

9.17

-1.5%↓

Search

Simulations Plus Inc

Gesloten

SectorGezondheidszorg

19.89 6.19

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

18.6

Max

20.02

Belangrijke statistieken

By Trading Economics

Inkomsten

1.4M

676K

Verkoop

961K

18M

K/W

Sectorgemiddelde

48.528

87.826

EPS

-0.034

Dividendrendement

0.48

Winstmarge

3.67

Werknemers

212

EBITDA

-3M

2.3M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+0.48% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

0.48%

2.26%

Volgende Winsten

2 apr 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

13M

381M

Vorige openingsprijs

13.7

Vorige sluitingsprijs

19.89

Nieuwssentiment

By Acuity

50%

50%

183 / 361 Rangschikking in Healthcare

Simulations Plus Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

13 jan 2026, 19:05 UTC

Belangrijke Marktbewegers

Travere Therapeutics Shares Fall After FDA Extends Filspari Review

13 jan 2026, 23:41 UTC

Marktinformatie

Nikkei May Rise on Japan Election Hopes -- Market Talk

13 jan 2026, 23:41 UTC

Marktinformatie

Global Equities Roundup: Market Talk

13 jan 2026, 23:33 UTC

Marktinformatie

Gold Edges Higher, Supported by Ongoing Geopolitical Tensions -- Market Talk

13 jan 2026, 23:13 UTC

Acquisities, Fusies, Overnames

JD Logistics Plans to Withdraw Listing Status of Deppon Logistics From Shanghai Stock Exchange

13 jan 2026, 23:10 UTC

Acquisities, Fusies, Overnames

JD Logistics Makes Cash Offer to Buy Deppon Logistics Shares It Doesn't Already Own

13 jan 2026, 23:03 UTC

Marktinformatie

Woodside's Sales Revenue Likely Fell 13% in 4Q -- Market Talk

13 jan 2026, 21:50 UTC

Acquisities, Fusies, Overnames

Netflix Preparing to Make Warner Bid All-Cash -- WSJ

13 jan 2026, 21:50 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Basic Materials Roundup: Market Talk

13 jan 2026, 21:20 UTC

Acquisities, Fusies, Overnames

Versant Media: Katz Will Continue to Lead Day-To-Day Ops of FTN

13 jan 2026, 21:20 UTC

Acquisities, Fusies, Overnames

Versant Media: Transaction Strengthens Distribution Footprint and Expands Free-To-Watch Portfolio >VSNT

13 jan 2026, 21:20 UTC

Acquisities, Fusies, Overnames

Versant Media: Jonathan Katz, FTN's Founder, Has Joined VERSANT, Reporting to David Pietrycha >VSNT

13 jan 2026, 21:15 UTC

Acquisities, Fusies, Overnames

VERSANT Completes Acquisition Of Free TV Networks >VSNT

13 jan 2026, 21:08 UTC

Acquisities, Fusies, Overnames

Array Digital Infrastructure Declares Special Dividend of $10.25 >AD

13 jan 2026, 20:39 UTC

Marktinformatie

Silver Settles at Another New High -- Market Talk

13 jan 2026, 20:21 UTC

Marktinformatie

Oil Futures Extend Rally On Rising Iran Tensions -- Market Talk

13 jan 2026, 20:17 UTC

Marktinformatie

U.S. Natural Gas Edges Up on Coming Weather -- Market Talk

13 jan 2026, 19:08 UTC

Acquisities, Fusies, Overnames

Super Micro Computer Is an AI Winner. Sell the Stock Anyway, Goldman Sachs Says. -- Barrons.com

13 jan 2026, 19:03 UTC

Winsten

Double-Digit Earnings Growth Could Continue. It Still Might Not Satisfy Investors. -- Barrons.com

13 jan 2026, 18:50 UTC

Winsten

JPMorgan's Unusual Quarter Weighs on Shares. How Apple Plays a Role. -- Barrons.com

13 jan 2026, 17:54 UTC

Marktinformatie

UnitedHealth Reaffirms 2025 Guidance After Senate Report -- Market Talk

13 jan 2026, 17:50 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Global Equities Roundup: Market Talk

13 jan 2026, 17:50 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Netflix Will Be a Winner No Matter How Warner Saga Ends -- Market Talk

13 jan 2026, 17:49 UTC

Marktinformatie

Analysts Call For Potential Record Ethanol Output -- Market Talk

13 jan 2026, 17:38 UTC

Marktinformatie

Merck CEO Sees $5B Market for Cidara's Flu Antiviral -- Market Talk

13 jan 2026, 17:20 UTC

Marktinformatie

Financial Services Roundup: Market Talk

13 jan 2026, 17:20 UTC

Marktinformatie

Health Care Roundup: Market Talk

13 jan 2026, 17:20 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Basic Materials Roundup: Market Talk

13 jan 2026, 17:19 UTC

Marktinformatie

Credit Cards Present Opportunity, Potential Obstacle for JPMorgan -- Market Talk

13 jan 2026, 17:15 UTC

Marktinformatie

Merck CEO Sees Eventual Growth After Keytruda Exclusivity Expires -- Market Talk

Peer Vergelijking

Prijswijziging

Simulations Plus Inc Prognose

Koersdoel

By TipRanks

0.48% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 19 USD  0.48%

Hoogste 19 USD

Laagste 19 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Simulations Plus Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

5 ratings

2

Buy

3

Hold

0

Sell

Sentiment

By Acuity

183 / 361 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
help-icon Live chat